Revolutionary Cancer Testing Technique Expands Across English Hospitals

A groundbreaking cancer diagnostic method has been cleared for large-scale implementation across NHS hospitals, promising to transform patient outcomes and increase availability to critical genetic analysis. Whole Genome Sequencing (WGS), which identifies the types and causes of cancers by analysing a patient’s DNA, is now being rolled out across the East of England following a pioneering preservation method developed at Addenbrooke’s Hospital in Cambridge. The innovation allows biological specimens to be preserved in a special solution and moved at standard temperature, removing the existing obligation for costly minus 80 degrees Celsius cryogenic storage. The expansion, introduced at the end of 2025, enables hospitals such as Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital and Ipswich Hospital to make available the test to more patients, potentially preventing avoidable surgical intervention and improving treatment outcomes across the region.

A Individual’s Journey to Clarity

Laraine Chung’s situation illustrates how WGS can fundamentally alter a patient’s medical trajectory. The 63-year-old care worker from Peterborough discovered she had a tumour behind her left eye the previous year, but early investigations proved inconclusive about its character. Confronted with the possibility of intricate procedures that could jeopardise her eyesight and risk affecting her brain and facial structures, Chung bore the burden of an unclear path ahead. However, her receipt of WGS testing at Addenbrooke’s Hospital delivered the turning point her clinical team critically required to chart a better direction forward.

The genetic analysis showed that Chung’s tumour was a benign meningioma, a diagnosis that substantially transformed her treatment plan. Rather than proceeding with extensive and invasive surgery with lengthy recuperation, she needed a far less complex procedure. “Without the test, I would have undergone significantly more complex surgery, and it would have taken even more time to recover,” Chung reflected. The four-times grandmother described the moment she received her results as a deep sense of relief for both herself and her family, knowing that her vision could be protected and her ordeal substantially cut short.

The Study Behind the Discovery

Whole Genome Sequencing represents a fundamental transformation in cancer diagnostics, offering clinicians an unparalleled insight into the DNA composition of malignant and benign tumours alike. By analysing the entire genomic sequence of a patient’s cancer cells, WGS allows medical teams to identify not merely what type of cancer is occurring, but crucially, what specific genetic mutations are driving its growth. This granular understanding allows oncologists to customise therapeutic approaches with exceptional accuracy, steering patients away from unnecessary procedures and towards interventions most probable to work. The technology has already demonstrated significant impact across the NHS, yet availability was restricted by practical obstacles that the new storage method now addresses.

How Whole Genome Sequencing Process Works

When a tissue biopsy is extracted from a patient, it contains invaluable genetic information that can inform treatment decisions. However, the genetic material within these samples deteriorates quickly, usually within hours, unless properly maintained. Traditionally, labs have stored samples at negative 80 degrees Celsius, a process demanding specialist equipment and transport infrastructure unavailable at many hospital sites. The advanced preservation method now used throughout the East of England stabilises the genetic material chemically, enabling secure transportation at room temperature and dramatically expanding access to this life-changing diagnostic capability.

• Identifies specific cancer types and genetic mutations fuelling cancer development
• Allows customised therapy choice based on individual genetic profiles
• Uncovers causes of cancers of uncertain aetiology for precision treatment
• Guides clinicians against avoidable invasive surgical procedures

Eliminating Logistical Barriers to Care

For some time, the primary obstacle to scaling Whole Genome Sequencing across the NHS has not been technical expertise, but rather the operational hurdles of transporting fragile biological samples to regional testing laboratories. Many hospitals, especially those in rural and isolated locations, lack the specialised cryogenic facilities needed to maintain genetic material during transport to centres like Cambridge University Hospitals NHS Foundation Trust. This facility deficit has essentially established a dual-tier arrangement, where patients at well-equipped teaching hospitals access advanced diagnostic services whilst those at smaller district hospitals stay unable to utilise the same life-preserving technology. The novel preservation technique substantially resolves this disparity.

The deployment throughout the eastern region, beginning at the end of 2025, constitutes a watershed moment in expanding access to advanced cancer diagnostics. Hospitals including Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital, and Ipswich Hospital can now participate in genome sequencing programmes formerly beyond their reach. Dr Jeffrey Rubasingham, consultant clinical oncologist at King’s Lynn, emphasises the profound effect: “This removes the need for minus 80C sample freezing and specialist transportation, and facilitates advanced experimental treatments when standard treatment options have been exhausted.” The removal of these logistical constraints is set to broaden diagnostic precision to thousands of additional patients annually.

The Ambient Temperature Solution

The innovative conservation method, created at Addenbrooke’s Hospital, utilises a chemical stabilising solution that safeguards DNA samples from breakdown without needing deep freezing. Rather than freezing samples at minus 80 degrees Celsius, tissue specimens are placed in this compound, which arrests the natural deterioration of genetic material whilst enabling reliable transport at standard room temperature. This refined technique eliminates the necessity of expensive cryogenic equipment and expert delivery providers, significantly lowering both financial burden and operational difficulty. The solution sustains biological integrity throughout transit, ensuring that biological specimens reaches diagnostic facilities in optimal condition for examination, irrespective of travel distance or time.

• Preserves genetic material using chemical preservation rather than cryogenic freezing
• Enables secure specimen delivery at room temperature across hospital networks
• Avoids requirement for expensive cryogenic equipment and specialised logistics
• Protects genetic stability throughout extended transit periods to laboratory facilities

Nationwide Expansion and Recognition

The success of the ambient storage method in the East of England has prompted careful evaluation of a countrywide expansion across NHS trusts. Leading medical professionals and NHS leadership understand the transformative potential of this advancement to democratise access to Whole Genome Sequencing across the country. The approach’s ease of use and cost-effectiveness have attracted strong backing from cancer specialists, who consider it essential infrastructure for modern oncology. Early responses from taking-part centres has been extremely encouraging, with medical staff reporting effortless embedding into established procedures and markedly enhanced clinical results. This forward direction points to the likelihood that in the years ahead, genetic sequencing could be standard procedure rather than a privilege reserved for people living close to major testing centres.

Recognition of this breakthrough extends beyond the NHS, with worldwide cancer research institutions acknowledging its significance for global healthcare systems. The innovation tackles a fundamental challenge that has long constrained diagnostic accuracy in distant and poorly-served communities. Cancer patient advocates have championed the development, stressing how technology-related obstacles have historically generated postcode lotteries in cancer treatment. Laraine Chung’s case exemplifies the life-changing impact: her access to testing at Addenbrooke’s preserved not only her vision but also prevented excessive surgical procedures. As the technique gains traction, NHS decision-makers increasingly view funding for preservation techniques as essential infrastructure, equivalent to investing in diagnostic tools.

Environmental and Medical Impact

The transition away from ultra-cold freezing technology carries substantial environmental advantages alongside therapeutic benefits. Ultra-low freezers operating at minus 80 degrees Celsius require significant energy consumption on an ongoing basis, making a notable contribution to hospital carbon footprints. By removing this need, the room temperature preservation method decreases power demand and corresponding environmental impacts across NHS organisations taking part. Simultaneously, the decrease in specialist delivery services and specialised freezing transport reduces fuel usage and logistics-related pollution. These environmental gains enhance the therapeutic outcomes, demonstrating how healthcare innovation can at the same time enhance patient care and sustainability objectives, bringing cancer services into line with NHS zero-carbon targets.

What This Signifies for Cancer Patients

For cancer patients across East of England hospitals, the implementation of room temperature preservation represents a tangible shift in availability of potentially life-saving diagnostics. Previously, patients at smaller hospitals faced a geographical disadvantage: their tissue samples deteriorated during movement to centralised testing laboratories, making them unfit for Whole Genome Sequencing analysis. Now, with samples stabilised in preserving solution, patients at Queen Elizabeth Hospital King’s Lynn, Peterborough City Hospital and Ipswich Hospital have access to the same advanced genetic testing as those cared for at major research centres. This development directly addresses what many characterise as postcode lottery healthcare, where health outcomes were largely determined by location rather than clinical need.

The practical implications extend beyond mere convenience. Quicker, more dependable access to WGS enables oncologists to identify precisely which cancers patients have and which treatment options will prove most effective. For some patients, this speeds up diagnosis by days or weeks—critical time when cancer is advancing. Additionally, patients may qualify for cutting-edge clinical trials providing experimental treatments not accessible via standard NHS pathways. Laraine Chung’s experience illustrates the human dimension: her test results not only protected her vision but spared her from unnecessarily complex surgery and its lengthy recovery period. As the technique expands further, thousands more patients should benefit from similar advantages.